MatchMedi
한국어

Research record

Tunlametinib + nivolumab unresolved lead

A remembered real-world combination that MatchMedi tracks carefully without presenting it as proven trial evidence.

What this is

A remembered real-world combination that MatchMedi tracks carefully without presenting it as proven trial evidence.

Why it may come up

  • user-provided lived context
  • after PD-1/PD-L1 failure

What not to assume

  • Lived experience only.
  • Must not be treated as standard of care.
  • Must not be merged with belvarafenib/cobimetinib/nivolumab evidence.

At a glance

Tunlametinib + nivolumab unresolved lead

Lived experience onlyPatient or caregiver story, not medical evidence.
Type
Targeted therapy
Mutation result
NRAS
Where
China, Unknown
Evidence status
Still unclear
Last checked
2026-05-21

What we know

  • User reports this was prescribed after PD-1/PD-L1 failure in Beijing with nivolumab.
  • Tunlametinib itself has China NMPA and trial support in NRAS-mutant melanoma that has spread or cannot be removed easily.
  • A fresh public search found nearby trial concepts, including binimetinib plus nivolumab and belvarafenib/cobimetinib/nivolumab, but those are not the same as tunlametinib plus nivolumab.

What is unclear

  • Exact public trial or publication for tunlametinib plus nivolumab in melanoma is not found.
  • The U.S. oncologist's remembered link may have referred to another MEK/RAF plus PD-1 trial, a conference abstract, or a non-U.S. registry record.

Questions to ask

  • Can the physician provide the trial record, protocol, or publication?
  • Is this local protocol, off-label combination practice, or compassionate access?
  • What monitoring plan is used for duration of response and progression?

Timeline

  1. research-gap2026: Unresolved combination lead

    The drug and NRAS context are sourced; the exact nivolumab combination is not yet sourced.

Related trial leads

NCT03973151

Study of HL-085 in NRAS Mutant Advanced Melanoma

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant melanoma that has spread or cannot be removed easily.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

NCT06008106

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

NCT04375527

Binimetinib and nivolumab in BRAF V600 wild-type melanoma

Supports the broader research concept of MEK inhibitor plus PD-1 inhibitor in melanoma, but not tunlametinib specifically.

Do not use this as evidence for tunlametinib plus nivolumab.

NCT04835805

Belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab in NRAS-mutant advanced melanoma

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

Related cohort stories